Integrative Genomic Profiling of Human Prostate Cancer

Overview

Journal Cancer Cell

Publisher Cell Press

Specialty Oncology

Date 2010 Jun 29

PMID 20579941

Citations 2197

Authors

Barry S Taylor

Nikolaus Schultz

Haley Hieronymus

Anuradha Gopalan

Yonghong Xiao

Brett S Carver

Vivek K Arora

Poorvi Kaushik

Ethan Cerami

Boris Reva

Yevgeniy Antipin

Nicholas Mitsiades

Thomas Landers

Igor Dolgalev

John E Major

Manda Wilson

Nicholas D Socci

Alex E Lash

Adriana Heguy

James A Eastham

Howard I Scher

Victor E Reuter

Peter T Scardino

Chris Sander

Charles L Sawyers

William L Gerald

Affiliations

Soon will be listed here.

Abstract

Annotation of prostate cancer genomes provides a foundation for discoveries that can impact disease understanding and treatment. Concordant assessment of DNA copy number, mRNA expression, and focused exon resequencing in 218 prostate cancer tumors identified the nuclear receptor coactivator NCOA2 as an oncogene in approximately 11% of tumors. Additionally, the androgen-driven TMPRSS2-ERG fusion was associated with a previously unrecognized, prostate-specific deletion at chromosome 3p14 that implicates FOXP1, RYBP, and SHQ1 as potential cooperative tumor suppressors. DNA copy-number data from primary tumors revealed that copy-number alterations robustly define clusters of low- and high-risk disease beyond that achieved by Gleason score. The genomic and clinical outcome data from these patients are now made available as a public resource.

Citing Articles

EphB4-ephrin-B2 are targets in castration resistant prostate cancer.

Li G, Ma B, Zhang S, Liu R, Siddiqi I, Sali A Br J Cancer. 2025; .

PMID: 40044981 DOI: 10.1038/s41416-025-02942-5.

Unveiling Racial Disparities in Localized Prostate Cancer: A Systems-Level Exploration of the lncRNA Landscape.

Morgan R, Hazard E, Savage S, Halbert C, Gattoni-Celli S, Hardiman G Genes (Basel). 2025; 16(2).

PMID: 40004558 PMC: 11855151. DOI: 10.3390/genes16020229.

The Landscape of Prostate Tumour Methylation.

Arbet J, Yamaguchi T, Shiah Y, Hugh-White R, Wiggins A, Oh J bioRxiv. 2025; .

PMID: 39990314 PMC: 11844408. DOI: 10.1101/2025.02.07.637178.

A Novel Molecular Profile of Hormone-Sensitive Prostate Cancer Defines High Risk Patients.

Piombino C, Nasso C, Bettelli S, Manfredini S, Vitale M, Pipitone S Cancer Med. 2025; 14(4):e70472.

PMID: 39980141 PMC: 11842281. DOI: 10.1002/cam4.70472.

Uncoupling of Akt and mTOR signaling drives resistance to Akt inhibition in PTEN loss prostate cancers.

Mao N, Lee Y, Salsabeel N, Zhang Z, Li D, Kaur H Sci Adv. 2025; 11(6):eadq3802.

PMID: 39919177 PMC: 11804928. DOI: 10.1126/sciadv.adq3802.

References

Singh D, Febbo P, Ross K, Jackson D, Manola J, Ladd C . Gene expression correlates of clinical prostate cancer behavior. Cancer Cell. 2002; 1(2):203-9. DOI: 10.1016/s1535-6108(02)00030-2. View

Wang Y, Moorhead M, Karlin-Neumann G, Falkowski M, Chen C, Siddiqui F . Allele quantification using molecular inversion probes (MIP). Nucleic Acids Res. 2005; 33(21):e183. PMC: 1301601. DOI: 10.1093/nar/gni177. View

Pleasance E, Stephens P, OMeara S, McBride D, Meynert A, Jones D . A small-cell lung cancer genome with complex signatures of tobacco exposure. Nature. 2009; 463(7278):184-90. PMC: 2880489. DOI: 10.1038/nature08629. View

Hieronymus H, Lamb J, Ross K, Peng X, Clement C, Rodina A . Gene expression signature-based chemical genomic prediction identifies a novel class of HSP90 pathway modulators. Cancer Cell. 2006; 10(4):321-30. DOI: 10.1016/j.ccr.2006.09.005. View

Kim J, Dhanasekaran S, Mehra R, Tomlins S, Gu W, Yu J . Integrative analysis of genomic aberrations associated with prostate cancer progression. Cancer Res. 2007; 67(17):8229-39. DOI: 10.1158/0008-5472.CAN-07-1297. View

Chitale D, Gong Y, Taylor B, Broderick S, Brennan C, Somwar R . An integrated genomic analysis of lung cancer reveals loss of DUSP4 in EGFR-mutant tumors. Oncogene. 2009; 28(31):2773-83. PMC: 2722688. DOI: 10.1038/onc.2009.135. View

Lapointe J, Li C, Giacomini C, Salari K, Huang S, Wang P . Genomic profiling reveals alternative genetic pathways of prostate tumorigenesis. Cancer Res. 2007; 67(18):8504-10. DOI: 10.1158/0008-5472.CAN-07-0673. View

Tomlins S, Laxman B, Varambally S, Cao X, Yu J, Helgeson B . Role of the TMPRSS2-ERG gene fusion in prostate cancer. Neoplasia. 2008; 10(2):177-88. PMC: 2244693. DOI: 10.1593/neo.07822. View

Jones S, Zhang X, Parsons D, Cheng-Ho Lin J, Leary R, Angenendt P . Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science. 2008; 321(5897):1801-6. PMC: 2848990. DOI: 10.1126/science.1164368. View

10.

Wood L, Parsons D, Jones S, Lin J, Sjoblom T, Leary R . The genomic landscapes of human breast and colorectal cancers. Science. 2007; 318(5853):1108-13. DOI: 10.1126/science.1145720. View

11.

Tran C, Ouk S, Clegg N, Chen Y, Watson P, Arora V . Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science. 2009; 324(5928):787-90. PMC: 2981508. DOI: 10.1126/science.1168175. View

12.

Dong J . Prevalent mutations in prostate cancer. J Cell Biochem. 2005; 97(3):433-47. DOI: 10.1002/jcb.20696. View

13.

Mucci L, Pawitan Y, Demichelis F, Fall K, Stark J, Adami H . Nine-gene molecular signature is not associated with prostate cancer death in a watchful waiting cohort. Cancer Epidemiol Biomarkers Prev. 2008; 17(1):249-51. DOI: 10.1158/1055-9965.EPI-07-0722. View

14.

Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M . A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004; 351(27):2817-26. DOI: 10.1056/NEJMoa041588. View

15.

Koon H, Ippolito G, Banham A, Tucker P . FOXP1: a potential therapeutic target in cancer. Expert Opin Ther Targets. 2007; 11(7):955-65. PMC: 4282158. DOI: 10.1517/14728222.11.7.955. View

16.

Greenman C, Stephens P, Smith R, Dalgliesh G, Hunter C, Bignell G . Patterns of somatic mutation in human cancer genomes. Nature. 2007; 446(7132):153-8. PMC: 2712719. DOI: 10.1038/nature05610. View

17.

Mucci L, Pawitan Y, Demichelis F, Fall K, Stark J, Adami H . Testing a multigene signature of prostate cancer death in the Swedish Watchful Waiting Cohort. Cancer Epidemiol Biomarkers Prev. 2008; 17(7):1682-8. PMC: 2536630. DOI: 10.1158/1055-9965.EPI-08-0044. View

18.

He W, Sciavolino P, Wing J, Augustus M, Hudson P, Meissner P . A novel human prostate-specific, androgen-regulated homeobox gene (NKX3.1) that maps to 8p21, a region frequently deleted in prostate cancer. Genomics. 1997; 43(1):69-77. DOI: 10.1006/geno.1997.4715. View

19.

Carver B, Tran J, Gopalan A, Chen Z, Shaikh S, Carracedo A . Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate. Nat Genet. 2009; 41(5):619-24. PMC: 2835150. DOI: 10.1038/ng.370. View

20.

Perner S, Demichelis F, Beroukhim R, Schmidt F, Mosquera J, Setlur S . TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. Cancer Res. 2006; 66(17):8337-41. DOI: 10.1158/0008-5472.CAN-06-1482. View